ArticleChemical science2020
Target-driven supramolecular self-assembly for selective amyloid-β photooxygenation against Alzheimer's disease.
Article in Chemical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 60 citations in OpenAlex.
- Assembling peptides for treating Alzheimer's disease: a supramolecular perspective.RSC advances · 2026Review
- Recent advances in self-assembled nanoplatforms for central nervous system disorders therapy: Design principles, multifunctional strategies, and therapeutic applications.Materials today. Bio · 2026Review
- Programmable next-generation supramolecular self-assembled materials as drug delivery systems.Bioactive materials · 2026Review
- Topology- and sequence-controlled β-amyloid recognition by a KLVFF/transferrin-functionalized csq porphyrinic zirconium MOF (PCN-222).Frontiers in chemistry · 2026Article
- Photothermal and Photodynamic Strategies for Diagnosis and Therapy of Alzheimer's Disease by Modulating Amyloid-β Aggregation.Biosensors · 2025Review
- Structure-based discovery of forsythoside A as an effective inhibitor to reduce the neurotoxicity of amyloid β.Communications chemistry · 2025Article
- Photodynamic and Photothermal Therapies using Nanotechnology Approach in Alzheimer's Disease.Current neuropharmacology · 2025Review
- A Photolabile Curcumin-Diazirine Analogue Enables Phototherapy with Physically and Molecularly Produced Light for Alzheimer's Disease Treatment.Angewandte Chemie (International ed. in English) · 2023Article
- Controlled and Selective Photo-oxidation of Amyloid-β Fibrils by OligomericACS applied materials & interfaces · 2022Article
- Modeling Alzheimer's Disease inBiomedicines · 2022Review
- Nanomaterials for Modulating the Aggregation of β-Amyloid Peptides.Molecules (Basel, Switzerland) · 2021Review
- Peptide-Tetrapyrrole Supramolecular Self-Assemblies: State of the Art.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photo-oxygenation of β-amyloid (Aβ) has been considered an efficient way to inhibit Aβ aggregation in Alzheimer's disease (AD). However, current photosensitizers cannot simultaneously achieve enhanced blood-brain barrier (BBB) permeability and selective photooxygenation of Aβ, leading to poor therapeutic efficacy, severe off-target toxicity, and substandard bioavailability. Herein, an Aβ target-driven supramolecular self-assembly (PKNPs) with enhanced BBB penetrability and switchable photoactivity is designed and demonstrated to be effective in preventing Aβ aggregation
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.